MAIA Biotechnology Inc. (MAIA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
444 WEST LAKE STREET, SUITE 1700 CHICAGO, IL 60606 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 7,150,695 | 10,950,927 | |||
| Cash and cash equivalents | 7,150,695 | 10,950,927 | |||
| Other undisclosed current assets | 413,357 | 857,110 | |||
| Total current assets: | 7,564,052 | 11,808,037 | |||
| Noncurrent Assets | |||||
| Deferred costs | 211,203 | ||||
| Other noncurrent assets | 2,800 | 2,800 | |||
| Total noncurrent assets: | 2,800 | 214,003 | |||
| TOTAL ASSETS: | 7,566,852 | 12,022,040 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,937,153 | 3,268,906 | |||
| Accounts payable | 1,638,546 | 1,165,505 | |||
| Accrued liabilities | 3,298,607 | 2,103,401 | |||
| Total current liabilities: | 4,937,153 | 3,268,906 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed noncurrent liabilities | 2,152,188 | 245,341 | |||
| Total noncurrent liabilities: | 2,152,188 | 245,341 | |||
| Total liabilities: | 7,089,341 | 3,514,247 | |||
| Equity | |||||
| Equity, attributable to parent | 477,511 | 8,507,793 | |||
| Common stock | 1,699 | 1,096 | |||
| Additional paid in capital | 64,472,249 | 52,729,942 | |||
| Accumulated other comprehensive loss | (16,260) | (15,973) | |||
| Accumulated deficit | (63,980,177) | (44,207,272) | |||
| Total equity: | 477,511 | 8,507,793 | |||
| TOTAL LIABILITIES AND EQUITY: | 7,566,852 | 12,022,040 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Operating expenses | (20,182,381) | (16,176,201) | ||
| Other operating expense, net (Other undisclosed Other operating expense, net) | ||||
| Other undisclosed operating income | ||||
| Operating loss: | (20,182,381) | (16,176,201) | ||
| Nonoperating income (Investment Income, Nonoperating) | 34,490 | 1,870 | ||
| Interest and debt expense | (6,863) | (6,967) | ||
| Loss from continuing operations before equity method investments, income taxes: | (20,154,754) | (16,181,298) | ||
| Other undisclosed income from continuing operations before income taxes | 354,754 | 381,298 | ||
| Loss from continuing operations: | (19,800,000) | (15,800,000) | ||
| Other undisclosed net income (loss) | 27,095 | 30,721 | ||
| Net loss attributable to parent: | (19,772,905) | (15,769,279) | ||
| Other undisclosed net loss available to common stockholders, basic | (450,578) | |||
| Net loss available to common stockholders, diluted: | (19,772,905) | (16,219,857) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net loss: | (19,772,905) | (15,769,279) | ||
| Comprehensive loss: | (19,772,905) | (15,769,279) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (287) | (466,551) | ||
| Comprehensive loss, net of tax, attributable to parent: | (19,773,192) | (16,235,830) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.